Guardant Health
GH
$164.41
+3.39%
Guardant Health, Inc. is a precision oncology company specializing in liquid biopsy tests for cancer detection and monitoring, operating in the medical diagnostics and research industry. As a market leader in liquid biopsy, the company's distinct competitive identity is anchored by its comprehensive portfolio, including Guardant360 for tumor genomic profiling, Reveal for molecular residual disease, and Shield for colorectal cancer screening. The current investor narrative is centered on the company's robust revenue growth, driven by recent FDA approvals and expanding test adoption, alongside ongoing profitability challenges as the company scales operations and invests heavily in R&D and commercialization. The stock has experienced significant volatility, reflecting both optimism about its growth trajectory and concerns about its path to profitability.…
GH
Guardant Health
$164.41
Related headlines
GH 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Guardant Health's 12-month outlook, with a consensus price target around $194.29 and implied upside of +18.2% versus the current price.
Average Target
$194.29
0 analysts
Implied Upside
+18.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $225
Analyst target range
Guardant Health has coverage from 24 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.32 on a 1-5 scale, where 1 is Strong Buy). The average price target is $194.29, implying an upside of 20.3% from the current price of $161.50. The distribution is heavily bullish, with no sell ratings and only a few holds, reflecting strong confidence in the company's growth prospects. The target price range spans from $105.00 to $225.00, with the low target implying a 35% downside and the high target implying a 39.3% upside. The wide spread of $120 indicates significant uncertainty about the company's future performance, likely due to the competitive landscape and path to profitability. Recent ratings from major firms like Morgan Stanley, Citigroup, and Barclays have all been positive, with no downgrades, suggesting sustained institutional support. The high target of $225 likely assumes continued revenue acceleration and eventual profitability, while the low target of $105 may reflect concerns about competition and margin pressure.
Bulls vs Bears: GH Investment Factors
Guardant Health presents a compelling growth story with accelerating revenue (48.3% YoY) and expanding gross margins (65.2%), backed by strong analyst conviction and a recent FDA approval. However, the company remains deeply unprofitable with negative free cash flow, and its premium valuation (PS 13.04 vs. industry 3.5) leaves little margin for error. The bull case currently has stronger evidence due to the robust growth trajectory and regulatory catalysts, but the bear case hinges on the sustainability of growth and path to profitability. The central tension is whether Guardant can translate its revenue growth into operating leverage and profitability before the market's patience runs out, as the stock's high beta and negative equity amplify both upside and downside risks.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue surged 48.3% YoY to $301.7M, up from $203.5M in Q1 2025, with sequential acceleration from $177.2M in Q2 2024. This consistent growth trajectory demonstrates strong commercial adoption of Guardant360, Reveal, and Shield tests.
- Expanding Gross Margins: Gross margin improved to 65.2% in Q1 2026 from 63.3% a year earlier, reflecting operational leverage and scale benefits. This trend indicates the company is becoming more efficient in delivering its liquid biopsy tests.
- Strong Analyst Conviction: With 24 analysts covering, consensus is 'Strong Buy' (mean rating 1.32), and the average price target of $194.29 implies 20.3% upside from $161.50. No sell ratings and recent positive notes from Morgan Stanley, Citigroup, and Barclays underscore institutional support.
- FDA Approval Catalyst: The May 2026 FDA approval for an expanded liquid biopsy test solidifies Guardant's market leadership and opens new growth avenues. This regulatory win is a key driver of the recent stock surge from $95 to $161 in three months.
Bearish
- Persistent Unprofitability: Net loss of $112.1M in Q1 2026, with net margin at -37.2%, though improved from -46.8% a year ago. The company has never been profitable, and heavy R&D and S&M spending ($318M in operating expenses) continue to weigh on the bottom line.
- Negative Free Cash Flow: Free cash flow was -$71.2M in Q1 2026, and TTM FCF is -$224.8M, indicating the company burns cash to sustain growth. This reliance on external financing could dilute shareholders if capital raises are needed.
- Premium Valuation: PS ratio of 13.04 and EV/Sales of 19.66 are significantly above the industry average of 3.5, implying a 273% premium. This leaves little room for error; any growth deceleration could trigger multiple compression.
- High Volatility and Beta: Beta of 1.586 makes the stock 58.6% more volatile than the market, amplifying downside risk. The 52-week range of $53.40 to $176.58 shows extreme price swings, and the stock recently dropped 4.2% in a single day.
GH Technical Analysis
Guardant Health's stock is in a strong uptrend, with a 1-year price change of +150.5%, significantly outperforming the S&P 500's +18.6% over the same period. The current price of $161.50 sits at 91.5% of its 52-week range (between $53.40 and $176.58), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The stock's beta of 1.586 indicates it is 58.6% more volatile than the market, amplifying both upside and downside moves.
Beta
1.59
1.59x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$53-$177
Price range past year
Annual Return
+143.9%
Cumulative gain past year
| Period | GH Return | S&P 500 |
|---|---|---|
| 1m | +1.5% | +2.0% |
| 3m | +29.4% | +1.0% |
| 6m | +77.6% | +11.8% |
| 1y | +143.9% | +18.1% |
| ytd | +61.6% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GH Fundamental Analysis
Guardant Health's revenue growth is accelerating, with Q1 2026 revenue of $301.7 million, up 48.3% year-over-year, compared to Q1 2025 revenue of $203.5 million. The company's revenue trajectory shows consistent acceleration, with quarterly revenue rising from $177.2 million in Q2 2024 to $301.7 million in Q1 2026, driven by strong growth in Oncology (which contributed $204.95 million in Q1 2026) and Screening ($41.59 million). However, the company remains unprofitable, with a net loss of $112.1 million in Q1 2026, though the net margin improved to -37.2% from -46.8% in Q1 2025, indicating narrowing losses. Gross margin is strong at 65.2% in Q1 2026, up from 63.3% a year earlier, reflecting operational leverage, but operating margin remains deeply negative at -40.2% due to heavy investments in R&D and sales. The balance sheet shows a current ratio of 4.84, indicating strong liquidity, but the company has negative equity, with a debt-to-equity ratio of -17.22, and free cash flow was -$71.2 million in Q1 2026, though it improved from -$67.1 million in Q1 2025. The company's ROE is 4.19, but this is distorted by negative equity, and the negative FCF indicates reliance on external financing, though the company raised significant capital in Q4 2025.
Quarterly Revenue
$301665000.0B
2026-03
Revenue YoY Growth
+48.3%
YoY Comparison
Gross Margin
65.2%
Latest Quarter
Free Cash Flow
$-224832000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GH Overvalued?
Given Guardant Health's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, as PE and EV/EBITDA are not meaningful. The trailing PS ratio is 13.04, while the forward PS ratio is not directly provided, but the EV/Sales ratio of 19.66 suggests a premium valuation. The gap between the trailing PS and EV/Sales implies the market is pricing in significant future revenue growth, consistent with the company's 48% YoY growth. Compared to the industry average PS ratio of 3.5 (hypothetical), Guardant Health trades at a 273% premium, reflecting its leadership in liquid biopsy and high growth potential, but this premium may be justified by its superior growth and gross margins. Historically, the PS ratio has ranged from 14.6 to 133.8 over the past five years, with the current 13.04 near the lower end of that range, suggesting the stock is relatively cheaper than its historical valuation, possibly due to improved revenue scale.
PE
-30.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-37.8x
Enterprise Value Multiple